Pharmacotherapy of relapsed metastatic testicular cancer.
Standard
Pharmacotherapy of relapsed metastatic testicular cancer. / Kollmannsberger, C; Honecker, Friedemann; Bokemeyer, Carsten.
In: EXPERT OPIN PHARMACO, Vol. 9, No. 13, 13, 2008, p. 2259-2272.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pharmacotherapy of relapsed metastatic testicular cancer.
AU - Kollmannsberger, C
AU - Honecker, Friedemann
AU - Bokemeyer, Carsten
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published. OBJECTIVE: To review the treatment of patients with testicular cancer after failure of first-line chemotherapy. METHODS: A literature search was performed for studies investigating therapies for relapsed testicular cancer. RESULTS/CONCLUSIONS: The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.
AB - BACKGROUND: Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published. OBJECTIVE: To review the treatment of patients with testicular cancer after failure of first-line chemotherapy. METHODS: A literature search was performed for studies investigating therapies for relapsed testicular cancer. RESULTS/CONCLUSIONS: The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.
M3 - SCORING: Zeitschriftenaufsatz
VL - 9
SP - 2259
EP - 2272
JO - EXPERT OPIN PHARMACO
JF - EXPERT OPIN PHARMACO
SN - 1465-6566
IS - 13
M1 - 13
ER -
